Power Alley: Merck To Spend Up To $838 Million, With Infinimmune, To Get "First Refual" Rights -- On Human Memory B Cell Antibodies...

The Rahway company continues to invest in its 2030s future, here getting a first look at Infinimmune's high value antibody targets for various diseases (both viral and cancerous) -- to become candidates for therapies or vaccines.

Here's the latest, from Fierce Biotech:

. . .Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million.

The New Jersey pharma is tapping Infinimmune to hunt for antibodies for as-of-yet undisclosed targets. The $838 million total comes from an undisclosed upfront payment and future potential milestone payouts, according to a March 31 release. Once Infinimmune identifies a potential antibody under the deal, Merck will have the exclusive right to take over development and commercialization.

Infinimmune’s platform uses a large dataset sourced from human memory B cells, which the company believes makes its antibody candidates already primed to become new drugs. . . .

Onward, grinning. . . .

नमस्ते